Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Navlimetostat plus pembrolizumab and chemotherapy vs placebo plus pembrolizumab and chemotherapy in first-line metastatic NSCLC with homozygous MTAP deletion
jRCT2011260014Phase 2Recruiting
- Sponsor
- Bristol Myers Squibb
- Start
- Apr 2026
- Modality
- Small Molecules
01
Overview
Phase 2, randomised, double-blind trial of navlimetostat in non-small cell lung cancer (NSCLC) (4 arms), sponsored by Bristol Myers Squibb. Primary endpoint: Progression-free survival. Started Apr 2026; status: recruiting.
02
Drugs
navlimetostat
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on jRCT2011260014.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2011260014.